ScripWith the state-run Korea Drug Development Fund (KDDF), which plays a key role in providing R&D support to the country’s biopharma industry, already midway through its current 10-year term, the fun
ScripThe fourth quarter marked a continuation of weak earnings for many major South Korean pharma firms, hurt by factors including the continued impact of a long-running doctors’ protest against medical r
In VivoOne of the main topics of conversation at the beginning of 2025 is how pharma companies should build their pipelines and the rising role that China is playing. A widely-cited report from Stifel show
ScripMajor South Korean pharma firms have reported mixed earnings for the third quarter ended 30 September, with Yuhan logging strong earnings after the US approval of its novel lung cancer drug and Hanmi